No superiority with NOAC compared to standard care following TAVI - PACE-CME

No superiority with NOAC compared to standard care following TAVI

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Can targeting of IL-6 lead to CV protection in CKD?
Can targeting of IL-6 lead to CV protection in CKD?
ACC.21
Can targeting of IL-6 lead to CV protection in CKD?
- Paul Ridker, MD
Renal denervation as option for patients with hypertension despite medications
Renal denervation as option for patients with hypertension despite medications
ACC.21
Renal denervation as option for patients with hypertension despite medications
- Prof. Ajay Kirtane, MD
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
ACC.21
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
- Prof. Freek Verheugt, MD
No definite difference for primary endpoint but proven safety with ARNI in MI patients
No definite difference for primary endpoint but proven safety with ARNI in MI patients
ACC.21
No definite difference for primary endpoint but proven safety with ARNI in MI patients
- Prof. Marc Pfeffer, MD, PhD